IBSA Group establishes commercial operations in the U.S. - Press release

Parsippany, N.J. - July 30th, 2018

“IBSA has been present in the U.S. market with multiple products through third-party licensing agreements for several years,” said Aldo Donati, CEO of IBSA Pharma. “The decision to directly commercialize levothyroxine in the United States through its IBSA Pharma Inc. will allow the company to maximize the commercial value of the drug franchise as well as introduce other IBSA products, some currently awaiting FDA approval.”